As of early February, TrumpRx.gov displays only a stylized Oval Office portrait of the president and the words “Coming Soon.”In early 2025, Donald Trump Jr. joined the board of BlinkRx, a digital pharmacy company that later began marketing a service it says can stand up direct-to-consumer drug programs in as few as 21 days. Within…
FDA approves Olumiant as first systemic therapy for baldness form
The FDA has announced that it has approved Lilly’s Olumiant (baricitinib) oral tablets to treat adults with severe alopecia areata, a form of baldness resulting from the body attacking its hair follicles. Manifesting as patchy baldness, alopecia areata affects more than 300,000 people in the U.S. The incidence of alopecia areata is growing. “Access to…
FDA approves Pfizer’s tofacitinib for ankylosing spondylitis
Pfizer (NYSE:PFE) has received FDA approval for the supplemental New Drug Application (sNDA) for Xeljanz/Xeljanz XR (tofacitinib) as a treatment of adults with active ankylosing spondylitis (AS). About 350,000 Americans have the condition. The Xeljanz approval covers patients who had an insufficient response or intolerance to one or more tumor necrosis factor (TNF) blockers. Xeljanz…